RU2011100106A - Замещенные бензимидазолы для лечения нейрофиброматоза - Google Patents
Замещенные бензимидазолы для лечения нейрофиброматоза Download PDFInfo
- Publication number
- RU2011100106A RU2011100106A RU2011100106/15A RU2011100106A RU2011100106A RU 2011100106 A RU2011100106 A RU 2011100106A RU 2011100106/15 A RU2011100106/15 A RU 2011100106/15A RU 2011100106 A RU2011100106 A RU 2011100106A RU 2011100106 A RU2011100106 A RU 2011100106A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- formula
- halogen
- neurofibromatosis
- tautomer
- Prior art date
Links
- 208000009905 Neurofibromatoses Diseases 0.000 title claims abstract 14
- 201000004931 neurofibromatosis Diseases 0.000 title claims abstract 14
- 150000001556 benzimidazoles Chemical class 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 claims abstract 19
- 150000001875 compounds Chemical class 0.000 claims abstract 14
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract 12
- 150000002367 halogens Chemical class 0.000 claims abstract 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 9
- 238000000034 method Methods 0.000 claims abstract 9
- 150000003839 salts Chemical class 0.000 claims abstract 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 7
- 208000013355 benign neoplasm of brain Diseases 0.000 claims abstract 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 5
- 208000009798 Craniopharyngioma Diseases 0.000 claims abstract 4
- 208000001154 Dermoid Cyst Diseases 0.000 claims abstract 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract 4
- 208000003019 Neurofibromatosis 1 Diseases 0.000 claims abstract 4
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 claims abstract 4
- 210000002987 choroid plexus Anatomy 0.000 claims abstract 4
- 201000002222 hemangioblastoma Diseases 0.000 claims abstract 4
- 206010027191 meningioma Diseases 0.000 claims abstract 4
- 208000002761 neurofibromatosis 2 Diseases 0.000 claims abstract 4
- 208000022032 neurofibromatosis type 2 Diseases 0.000 claims abstract 4
- 210000004560 pineal gland Anatomy 0.000 claims abstract 4
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims abstract 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims abstract 3
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims abstract 3
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 3
- 230000002265 prevention Effects 0.000 claims abstract 3
- 125000001424 substituent group Chemical group 0.000 claims abstract 3
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 claims abstract 2
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims abstract 2
- 208000007538 neurilemmoma Diseases 0.000 claims 3
- -1 C 1 -C 6 alkyl Chemical group 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000003154 papilloma Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6115608P | 2008-06-13 | 2008-06-13 | |
| US61/061,156 | 2008-06-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011100106A true RU2011100106A (ru) | 2012-10-27 |
Family
ID=40956523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011100106/15A RU2011100106A (ru) | 2008-06-13 | 2009-06-11 | Замещенные бензимидазолы для лечения нейрофиброматоза |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110092546A1 (enExample) |
| EP (1) | EP2288354A1 (enExample) |
| JP (1) | JP2011524362A (enExample) |
| KR (1) | KR20110025827A (enExample) |
| CN (1) | CN102065859B (enExample) |
| AU (1) | AU2009257487B2 (enExample) |
| BR (1) | BRPI0915106A2 (enExample) |
| CA (1) | CA2726376A1 (enExample) |
| MX (1) | MX2010013683A (enExample) |
| RU (1) | RU2011100106A (enExample) |
| TW (1) | TW201004621A (enExample) |
| WO (1) | WO2009152288A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2668210T3 (da) | 2011-01-26 | 2020-08-24 | Celldex Therapeutics Inc | Anti-kit antistoffer og anvendelser deraf |
| RU2681730C2 (ru) | 2012-07-25 | 2019-03-12 | Селлдекс Терапьютикс Инк. | Антитела против kit и их применения |
| CN113975386A (zh) * | 2014-05-23 | 2022-01-28 | 塞尔德克斯医疗公司 | 嗜酸性粒细胞或肥大细胞相关病症的治疗 |
| KR101880015B1 (ko) | 2017-12-08 | 2018-07-19 | 아주대학교산학협력단 | 인터페론 감마를 유효성분으로 함유하는 신경섬유육종 예방 또는 치료용 조성물 |
| CN113784713A (zh) | 2019-01-11 | 2021-12-10 | 纳吉斯制药股份有限公司 | 白三烯合成抑制剂 |
| CN117460509B (zh) * | 2021-06-23 | 2025-03-28 | 正大天晴药业集团股份有限公司 | 作为c-Met激酶抑制剂的化合物治疗I型神经纤维瘤病的用途 |
| JP2024534693A (ja) * | 2021-10-08 | 2024-09-20 | ウニベルシテ クロード ベルナール リヨン １ | 組織球症若しくは頭蓋咽頭腫の治療又は予防における使用のためのベンズイミダゾール誘導体 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA007987B1 (ru) * | 2002-03-29 | 2007-02-27 | Чирон Корпорейшн | Замещённые бензазолы и их применение в качестве ингибиторов киназы raf |
| TW200804345A (en) * | 2005-08-30 | 2008-01-16 | Novartis Ag | Substituted benzimidazoles and methods of preparation |
| GB0609378D0 (en) * | 2006-05-11 | 2006-06-21 | Novartis Ag | Organic compounds |
| PE20130814A1 (es) * | 2006-08-30 | 2013-08-08 | Novartis Ag | Sales de benzimidazolil piridil eteres y formulaciones que las contienen |
| WO2008070616A2 (en) * | 2006-12-01 | 2008-06-12 | University Of Utah Research Foundation | METHODS AND COMPOSITIONS RELATED TO HIF-1α |
| EP2175885B1 (en) * | 2007-07-30 | 2016-10-12 | Ardea Biosciences, Inc. | Combinations of mek inhibitors and raf kinase inhibitors and uses thereof |
| WO2009114703A2 (en) * | 2008-03-12 | 2009-09-17 | Fox Chase Cancer Center | Combination therapy for the treatment of cancer |
-
2009
- 2009-06-11 EP EP09763578A patent/EP2288354A1/en not_active Ceased
- 2009-06-11 CA CA2726376A patent/CA2726376A1/en not_active Abandoned
- 2009-06-11 KR KR1020117000776A patent/KR20110025827A/ko not_active Withdrawn
- 2009-06-11 US US12/997,770 patent/US20110092546A1/en not_active Abandoned
- 2009-06-11 AU AU2009257487A patent/AU2009257487B2/en not_active Ceased
- 2009-06-11 JP JP2011513674A patent/JP2011524362A/ja not_active Withdrawn
- 2009-06-11 CN CN2009801221827A patent/CN102065859B/zh not_active Expired - Fee Related
- 2009-06-11 BR BRPI0915106A patent/BRPI0915106A2/pt not_active IP Right Cessation
- 2009-06-11 WO PCT/US2009/046971 patent/WO2009152288A1/en not_active Ceased
- 2009-06-11 RU RU2011100106/15A patent/RU2011100106A/ru not_active Application Discontinuation
- 2009-06-11 MX MX2010013683A patent/MX2010013683A/es not_active Application Discontinuation
- 2009-06-12 TW TW098119822A patent/TW201004621A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0915106A2 (pt) | 2016-02-10 |
| KR20110025827A (ko) | 2011-03-11 |
| AU2009257487B2 (en) | 2013-01-31 |
| CN102065859B (zh) | 2012-10-03 |
| EP2288354A1 (en) | 2011-03-02 |
| TW201004621A (en) | 2010-02-01 |
| CN102065859A (zh) | 2011-05-18 |
| AU2009257487A1 (en) | 2009-12-17 |
| WO2009152288A1 (en) | 2009-12-17 |
| CA2726376A1 (en) | 2009-12-17 |
| US20110092546A1 (en) | 2011-04-21 |
| MX2010013683A (es) | 2011-04-26 |
| JP2011524362A (ja) | 2011-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011100106A (ru) | Замещенные бензимидазолы для лечения нейрофиброматоза | |
| RU2008125055A (ru) | 2-(фенил или гетероцикло)-1h-фенантро[9.10-d]имидазолы в качестве ингибиторов mpges-1 | |
| RU2011146363A (ru) | Производные n-ацил-n-фенилпиперазина, используемые (кроме того) для профилактики или лечения диабета | |
| RU2012127334A (ru) | Производные 5-замещенного хиназолинона, содержащие их композиции и способы их применения | |
| JP2020503299A5 (enExample) | ||
| NZ590268A (en) | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | |
| AR057109A1 (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis | |
| JP2011502958A5 (enExample) | ||
| PE20110062A1 (es) | N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo | |
| NZ611528A (en) | Neprilysin inhibitors | |
| RU2011127451A (ru) | ПРОИЗВОДНЫЕ ТИЕНО[3,2-c]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ РАКА | |
| MY148375A (en) | Delta and epsilon crystal forms of imatinib mesylate | |
| RU2011140869A (ru) | Пиперазиновое соединение, ингибирующее простагландин-d-синтазу | |
| RU2008120850A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
| JP2011524362A5 (enExample) | ||
| RU2009131697A (ru) | Применение ингибитора trpm5 для регулирования секреции инсулина и гпп-1 | |
| JP2009501745A5 (enExample) | ||
| RU2011105059A (ru) | Применение производных пиримидиламинобензамида для лечения фиброза | |
| RU2372348C2 (ru) | Производные индолилмалеимида в качестве ингибиторов ркс | |
| EA200701780A1 (ru) | Противоопухолевое средство | |
| MY144623A (en) | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht 1f agonists | |
| JP2006503857A5 (enExample) | ||
| RU2015150287A (ru) | Новые соединения 3,4-дигидро-2н-изохинолин-1-она и 2,3-дигидроизоиндол-1-она | |
| JP2019529487A5 (enExample) | ||
| ZA200704913B (en) | 3-[2-(3-acylamino-2-oxo-2H-pyridin-1-YL)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20140616 |